These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12454567)

  • 21. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests.
    Borkowska A; Araszkiewicz A; Rajewski A; Rybakowski JK
    Neuropsychobiology; 2002; 46(2):85-9. PubMed ID: 12378125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessional symptoms associated with risperidone treatment.
    Mahendran R
    Aust N Z J Psychiatry; 1998 Apr; 32(2):299-301. PubMed ID: 9588312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone and cognitive functioning in elderly schizophrenic patients.
    Reznik I; Paleacu D
    Am J Geriatr Psychiatry; 2000; 8(2):177. PubMed ID: 10804081
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life and atypical antipsychotics.
    Rudnick A
    J Clin Psychopharmacol; 1998 Oct; 18(5):424-5. PubMed ID: 9790165
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of risperidone on hostility in schizophrenia.
    Czobor P; Volavka J; Meibach RC
    J Clin Psychopharmacol; 1995 Aug; 15(4):243-9. PubMed ID: 7593706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.
    Dinakar HS; Sobel RN; Bopp JH; Daniels A; Mauro S
    Psychiatr Serv; 2002 Jun; 53(6):755-7. PubMed ID: 12045315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A naturalistic outcome study of risperidone treatment among hospital patients.
    Negrón AE; Leiderman EA; Parkadavil M; Cienfuegos A; Javitt DC
    Psychiatr Serv; 1996 Oct; 47(10):1118-20. PubMed ID: 8890343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of risperidone on emotion recognition deficits in antipsychotic-naïve schizophrenia: a short-term follow-up study.
    Behere RV; Venkatasubramanian G; Arasappa R; Reddy N; Gangadhar BN
    Schizophr Res; 2009 Aug; 113(1):72-6. PubMed ID: 19545977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
    Kopala LC; Good KP; Honer WG
    J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
    Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R
    Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of Hunperdal Richter in psychiatry].
    Magyar GI; Fadgyas I
    Neuropsychopharmacol Hung; 2009 Jun; 11(2):111-5. PubMed ID: 19827319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone for exclusively negative symptoms.
    Lane HY; Liu CC; Chang WH
    Am J Psychiatry; 1999 Feb; 156(2):335. PubMed ID: 9989576
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
    Matsuda Y; Sato S; Iwata K; Furukawa S; Hatsuse N; Watanabe Y; Anzai N; Kishimoto T; Ikebuchi E
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):425-31. PubMed ID: 24506576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.